Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review

Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review

Min Li,&ast; Chenchen Wu,&ast; Yan Liu, Ranran Zhang, Qingqing Yang, Zhaoming Shi, Weihua Sun, Xiaolei Hu Department of Endocrinology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, People’s Republic of China&ast;These authors contributed equally to this...

Full description

Bibliographic Details
Main Authors:	Li M, Wu C, Liu Y, Zhang R, Yang Q, Shi Z, Sun W, Hu X
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-04-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	type 1 diabetes immune checkpoint inhibitors immune-related adverse reactions kn046
Online Access:	https://www.dovepress.com/autoimmune-polyendocrinopathy-induced-by-an-antibody-kn046-that-simult-peer-reviewed-fulltext-article-DMSO

Similar Items

Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
by: Mengge Ding, et al.
Published: (2023-05-01)

Root-Knot Nematode Resistance in Peanut
by: Jim Rich, et al.
Published: (2008-01-01)

Fairy Rings
by: Monica L. Elliott, et al.
Published: (2011-02-01)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
by: Yuwei Hao, et al.
Published: (2022-01-01)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
by: Dimitrios C. Ziogas, et al.
Published: (2023-05-01)

Checks and Balances in Autoimmune Vasculitis
by: Rebeca Hid Cadena, et al.
Published: (2018-02-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

An expedient route for the synthesis of an anti-HIV peptide Kn2-7: A TAG approach
by: Akshitha D. Nagaraja, et al.
Published: (2024-01-01)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
by: Adam Mor, et al.
Published: (2022-01-01)

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
by: Tomonori Makiguchi, et al.
Published: (2022-04-01)

Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction
by: Huili Wu, et al.
Published: (2022-12-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
by: Weiting Liang, et al.
Published: (2024-02-01)

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
by: Rena Pollack, et al.
Published: (2023-06-01)

Comparison of Acne Degree among Users of Disposable and KN95 Masks
by: Andi Nur Asrinawaty, et al.
Published: (2024-03-01)

6.046J Introduction to Algorithms (SMA 5503), Fall 2004
by: Leiserson, Charles Eric, et al.
Published: (2004)

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
by: Prasanna Duraisamy, et al.
Published: (2023-07-01)

Clinical analysis of 22 cases of cutaneous adverse reactions caused by molecular targeted antitumor agents and immune checkpoint inhibitors
by: Kui MU, et al.
Published: (2023-12-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system
by: Jiayu Shi, et al.
Published: (2020-02-01)

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
by: Rongbin Qi, et al.
Published: (2023-08-01)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
by: You-Cheng Zhang, et al.
Published: (2023-01-01)

Production of ginsenoside F1 using commercial enzyme Cellulase KN
by: Yu Wang, et al.
Published: (2016-04-01)

Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature
by: Yining Gao, et al.
Published: (2022-06-01)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
by: Johanna Matull, et al.
Published: (2020-11-01)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
by: Yosuke Shibata, et al.
Published: (2023-11-01)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
by: Judith A. Seidel, et al.
Published: (2018-03-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report
by: Nolan Holley, et al.
Published: (2024-03-01)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
by: Bruno Fattizzo, et al.
Published: (2022-04-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

6.046J / 18.410J Introduction to Algorithms, Fall 2001
by: Demaine, Erik D., et al.
Published: (2001)

Immunotherapy-induced adverse events in metastatic renal cell carcinoma: A case of rapid response and complex challenges
by: João Pedroso Lima, et al.
Published: (2024-03-01)

Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors  Combined with Chemotherapy
by: Ping XIAO, et al.
Published: (2022-04-01)

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
by: Lorenz Kocheise, et al.
Published: (2024-01-01)

Immune checkpoint inhibitor-associated sarcoidosis reaction
by: Parisa Keshtgar, et al.
Published: (2023-09-01)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
by: Maria Silvia Cona, et al.
Published: (2019-02-01)

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
by: Lorenz Kocheise, et al.
Published: (2024-01-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
by: Masayuki Ueno, et al.
Published: (2022-09-01)